CEO: Mary Kerr

Advent Contact: Kaasim Mahmood/Raj Parekh

Novel neurokinin antagonists

NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders. Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy and there are no approved treatments for it. IPF has been designated an orphan disease in both Europe and the USA. Preparations for the start of the Phase 2 trial to evaluate orvepitant as a treatment for disabling chronic cough associated with IPF are currently underway.

Advent founded NeRRe in 2012. NeRRe completed a £23M private financing in 2016.

NeRRe Therapeutics raises £23 million in oversubscribed Series B financing round